- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04382014
Pharmacokinetic Study on Three Formulations of Curcumin With Different Carriers
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
15 men and 15 women in good health conditions will be recruited for this project. The study has a randomized double-blinded crossover design with three treatments that include an equal dosage of curcumin as follows :
- 400 mg of curcumin extract,
- 400 mg of curcumin in rice oil,
- 400 mg of curcumin extract + 1.5 g omega-3 in MAG form.
For each of the above listed products, a natural product number (NPN) was requested to Health Canada and these number are currently pending.
Each participant will consume each of the three treatments in a random order with a minimum of 7 days washout phase between both treatments. Blood samples will be collected at time 0, 1, 2, 3, 4, 5, 6, 8, 10, and 24h (10 blood samples per participant per treatment) after taking the single dose intake. A questionnaire will allow documenting side effects throughout the study period. The analyses will be performed by ultra-high-performance liquid chromatography couples to a quadrupole mass spectrometer (UPLC/MS/MS). Samples will be analyzed in a blinded manner such that the student and research assistant will be blinded from the type of treatment and the time point they are analyzing. After performing all the analyses, sample identification will be decoded and pharmacokinetic data of the curcuminoids in each of the treatments will be plotted on a plasma concentration vs time curve. The parameters below will be calculated:
- Area under the curve (AUC) 0-24h (bioavailability);
- Area under the curve (AUC) 0-6h (absorption);
- Maximum concentration (Cmax);
- Time to reach the maximum concentration (Tmax);
- Half-life (if available).
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Melanie Plourde, PhD
- Phone Number: 45664 819-780-2220
- Email: melanie.plourde2@usherbrooke.ca
Study Locations
-
-
Quebec
-
Sherbrooke, Quebec, Canada, J1H 4C4
- Centre de recherche sur le vieillissement
-
Contact:
- Melanie Plourde, PhD
- Phone Number: 45664 819-780-2220
- Email: melanie.plourde2@usherbrooke.ca
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men or women between 18 and 50 years old (inclusive).
- Body mass index between 18,5 and 34,9 at the selection visit (inclusive).
- Normal to moderately high lipidemia (total cholesterol ≤ 240 mg / dl; LDL ≤ 160 mg / dl; Triglyceride ≤ 199 mg / dl).
- Women of child bearing potential must accept to use an effective contraceptive method for the duration of the study.
Exclusion Criteria:
- Allergy to fish or seafood.
- Special diet like a vegetarian or vegan diet.
- Tobacco.
- History of current or past alcohol and / or drug abuse.
- Current or past performance athlete.
- Malnutrition (assessed by albumin, hemoglobin and blood lipid levels).
- People consuming omega 3 fatty acid or curcumin supplements for more than 6 months.
- Medication affecting fat absorption (ie, Orlistat, Alli, etc.).
- Medication which interferes with the metabolization of the medication (ie, anticoagulants like coumadin or warfarin, aspirin is not an exclusion criterion (Watson et al, 2009))
- Medication which affects lipid metabolism (ie, all types of drugs to lower cholesterol or triglycerides).
- Medication which curcumin interacts with : angiotensin II blockers (losartan, valsartan), β-blockers (talinolol, celiprolol), calcium channels blockers (nifedipine), 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMG CoA) reductase inhibitors (rosuvastatin), antineoplastic agents (docetaxel, etoposide, tamoxifen, everolimus, sirolimus), antibiotics (norfloxacin), antidepressant (midazolam), sulfonamides (sulfasalazine), antidiabetics (gliclazide).
- Pregnant women or nursing women.
- Menopause or pre-menopause with amenorrhea > 6 months.
- Systemic disease: vasculitis, Lupus Erythrocyte Disseminated (SLE), sarcoidosis, cancer (except if in remission for more than 10 years and without cerebral involvement), uncompensated hypothyroidism, vitamin B12 deficiency not supplemented and / or complicated, diabetes, severe renal insufficiency.
- Abnormal liver, kidney or thyroid function; these conditions will not exclude a patient if he / she has been stabilized on treatment for at least 3 months and there has been no recent change in his / her medication.
- Cardiac event or recent major surgery (<6 months).
- History of thrombosis or haemorrhagic diathesis.
- Malabsorption disease such as pancreatitis, Crohn's disease or has had bariatric surgery.
- Neurodegenerative disease (Parkinson disease).
- Genetic disorder (Down syndrome).
- Known psychiatric history: schizophrenia, psychotic disorders, major affective disorder (bipolar disorder and major depression <5 years), panic disorder, Compulsive Obsessive Compulsive Disorder (OCD).
- Neurological disorder (Epilepsy, cerebral trauma with loss of consciousness, subarachnoid hemorrhage).
- Person who has donated blood or had significant blood loss in the 30 days prior to the start of the study.
- Not available to perform the 3 treatments.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MAG fish oil + Curcumin
The participant will arrive fasted at he research center.
After installing a catheter and drawing 5 mL of blood, the participants will be given one of the active comparator or the treatment.
The choice of the treatment/comparator will be random.
In this arm, the participant will receive 1 dose of 1,5 g MAG fish oil + 400 mg curcumin.
The participant will consume this unique dose with a standardized breakfast.
There will thereafter be blood sample collection over 24 h to evaluate the level of curcumin in the plasma and a side effect questionnaire will be administered to monitor side effects.
|
The intervention is a randomized double blind cross over design testing the pharmacokinetics of 1) curcumin combined with MAG fish oil as a carrier, 2) curcumin combined with rice bran oil as a carrier, and 3) curcumin extract. Treatments are randomly assigned on days 1, 8 and 15 of the clinical study. Blood samples will be collected at time 0, 1, 2, 3, 4, 5, 6, 8, 10 and 24h after taking the supplement. Each participant will perform all three treatments, with a minimum of 7 days between treatments. A questionnaire will document the side effects felt by participants. |
Active Comparator: Rice bran oil + Curcumin
The participant will arrive fasted at he research center.
After installing a catheter and drawing 5 mL of blood, the participants will be given one of the active comparator or the treatment.
The choice of the treatment/comparator will be random.
In this arm, the participant will receive 1 dose of rice bran oil + 400 mg curcumin.
The participant will consume this unique dose with a standardized breakfast.
There will thereafter be blood sample collection over 24 h to evaluate the level of curcumin in the plasma and a side effect questionnaire will be administered to monitor side effects.
|
The intervention is a randomized double blind cross over design testing the pharmacokinetics of 1) curcumin combined with MAG fish oil as a carrier, 2) curcumin combined with rice bran oil as a carrier, and 3) curcumin extract. Treatments are randomly assigned on days 1, 8 and 15 of the clinical study. Blood samples will be collected at time 0, 1, 2, 3, 4, 5, 6, 8, 10 and 24h after taking the supplement. Each participant will perform all three treatments, with a minimum of 7 days between treatments. A questionnaire will document the side effects felt by participants. |
Active Comparator: Curcumin extract
The participant will arrive fasted at he research center.
After installing a catheter and drawing 5 mL of blood, the participants will be given one of the active comparator or the treatment.
The choice of the treatment/comparator will be random.
In this arm, the participant will receive 1 dose of 400 mg curcumin.
The participant will consume this unique dose with a standardized breakfast.
There will thereafter be blood sample collection over 24 h to evaluate the level of curcumin in the plasma and a side effect questionnaire will be administered to monitor side effects.
|
The intervention is a randomized double blind cross over design testing the pharmacokinetics of 1) curcumin combined with MAG fish oil as a carrier, 2) curcumin combined with rice bran oil as a carrier, and 3) curcumin extract. Treatments are randomly assigned on days 1, 8 and 15 of the clinical study. Blood samples will be collected at time 0, 1, 2, 3, 4, 5, 6, 8, 10 and 24h after taking the supplement. Each participant will perform all three treatments, with a minimum of 7 days between treatments. A questionnaire will document the side effects felt by participants. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Determine the bioavailability of curcumin in combination with fish oil, rice oil or alone: Calculating the area under the curve (AUC) 0-48h as the first parameter of the PK
Time Frame: Treatments are randomly assigned on days 1, 8 and 15 of the clinical study. UPLC analyzes will be measured on plasma from blood samples collected at time 0, 1, 2, 3, 4, 5, 6, 8, 10 and 24 hours post-treatment.
|
Plasma curcumin levels will be measured by ultra-performance liquid chromatography (UPLC), each sample being performed randomly blindly.
After UPLC analyzes, area under the curve (AUC) 0-48 hours will be calculated, as the first parameter of the PK.
Statistical analyzes will then be performed on this PK parameter.
|
Treatments are randomly assigned on days 1, 8 and 15 of the clinical study. UPLC analyzes will be measured on plasma from blood samples collected at time 0, 1, 2, 3, 4, 5, 6, 8, 10 and 24 hours post-treatment.
|
Determine the bioavailability of curcumin in combination with fish oil, rice oil or alone: Calculating the AUC 0-6h (absorption study) as the second parameter of the PK
Time Frame: Treatments are randomly assigned on days 1, 8 and 15 of the clinical study. UPLC analyzes will be measured on plasma from blood samples collected at time 0, 1, 2, 3, 4, 5, 6, 8, 10 and 24 hours post-treatment.
|
Plasma curcumin levels will be measured by ultra-performance liquid chromatography (UPLC), each sample being performed randomly blindly.
After UPLC analyzes, AUC 0-6 hours (absorption study) will be calculated, as the second parameter of the PK.
Statistical analyzes will then be performed on this PK parameter.
|
Treatments are randomly assigned on days 1, 8 and 15 of the clinical study. UPLC analyzes will be measured on plasma from blood samples collected at time 0, 1, 2, 3, 4, 5, 6, 8, 10 and 24 hours post-treatment.
|
Determine the bioavailability of curcumin in combination with fish oil, rice oil or alone: Calculating the maximum concentration as the third parameter of the PK
Time Frame: Treatments are randomly assigned on days 1, 8 and 15 of the clinical study. UPLC analyzes will be measured on plasma from blood samples collected at time 0, 1, 2, 3, 4, 5, 6, 8, 10 and 24 hours post-treatment.
|
Plasma curcumin levels will be measured by ultra-performance liquid chromatography (UPLC), each sample being performed randomly blindly.
After UPLC analyzes, maximum concentration will be calculated, as the third parameter of the PK.
Statistical analyzes will then be performed on this PK parameter.
|
Treatments are randomly assigned on days 1, 8 and 15 of the clinical study. UPLC analyzes will be measured on plasma from blood samples collected at time 0, 1, 2, 3, 4, 5, 6, 8, 10 and 24 hours post-treatment.
|
Determine the bioavailability of curcumin in combination with fish oil, rice oil or alone: Calculating the time when the maximum concentration is reached, as the fourth parameter of the PK
Time Frame: Treatments are randomly assigned on days 1, 8 and 15 of the clinical study. UPLC analyzes will be measured on plasma from blood samples collected at time 0, 1, 2, 3, 4, 5, 6, 8, 10 and 24 hours post-treatment.
|
Plasma curcumin levels will be measured by ultra-performance liquid chromatography (UPLC), each sample being performed randomly blindly.
After UPLC analyzes, time when the maximum concentration is reached will be calculated, as the fourth parameter of the PK.
Statistical analyzes will then be performed on this PK parameter.
|
Treatments are randomly assigned on days 1, 8 and 15 of the clinical study. UPLC analyzes will be measured on plasma from blood samples collected at time 0, 1, 2, 3, 4, 5, 6, 8, 10 and 24 hours post-treatment.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Melanie Plourde, PhD, Université de Sherbrooke
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Antineoplastic Agents
- Curcumin
Other Study ID Numbers
- MaxSimil + curcumin
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on MAG fish oil + Curcumin OR Rice bran oil + Curcumin OR Curcumin extract
-
Universitas Sebelas MaretNot yet recruitingInflammation | Diabetes Mellitus, Type 2 | Body Weight | Insulin ResistanceIndonesia
-
Columbia UniversityWithdrawn
-
Ottawa Hospital Research InstituteUniversity of Ottawa; The Canadian College of Naturopathic Medicine; Lotte &... and other collaboratorsRecruitingGastric Cancer | Esophageal Cancer | Lung CancerCanada